Tugba Onder

Dr. Abdurrahman Yurtaslan Ankara Oncology Training And Research Hospital
Ankara, Turkey

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 16 publications

Crossing the milestone: landmark-based conditional survival after first-line CDK4/6 inhibitor therapy in HR+/HER2-metastatic breast cancer.

Crossing the milestone: landmark-based conditional survival after first-line CDK4/6 inhibitor therapy in HR+/HER2-metastatic breast cancer.

Journal: Breast cancer (Tokyo, Japan)

Published: May 29, 2026

Prognostic and Treatment-Specific Predictive Implications of HER2 Expression in RAS Wild-Type Metastatic Colorectal Cancer: A Multicenter Retrospective Real-World Study.

Prognostic and Treatment-Specific Predictive Implications of HER2 Expression in RAS Wild-Type Metastatic Colorectal Cancer: A Multicenter Retrospective Real-World Study.

Journal: Journal of clinical medicine

Published: April 19, 2026

Local Ablative Therapy in Breast Cancer Liver Metastases: Survival Outcomes and Prognostic Factors-A Single-Center Retrospective Study.

Local Ablative Therapy in Breast Cancer Liver Metastases: Survival Outcomes and Prognostic Factors-A Single-Center Retrospective Study.

Journal: Journal of clinical medicine

Published: March 28, 2026

Phenotypic Age Acceleration Predicts Survival Outcomes in HR+/HER2-Negative Metastatic Breast Cancer Treated With CDK4/6 Inhibitors: A Real-World Cohort Study.

Phenotypic Age Acceleration Predicts Survival Outcomes in HR+/HER2-Negative Metastatic Breast Cancer Treated With CDK4/6 Inhibitors: A Real-World Cohort Study.

Journal: Clinical breast cancer

Published: March 14, 2026

Clinical Significance of Achieving No Evidence of Disease in HER2-Positive Metastatic Breast Cancer: A Multicenter Study by Turkish Oncology Group (TOG).

Clinical Significance of Achieving No Evidence of Disease in HER2-Positive Metastatic Breast Cancer: A Multicenter Study by Turkish Oncology Group (TOG).

Journal: Cancers

Published: February 12, 2026

Biological aging enhances prognostic stratification beyond chronological age in breast cancer brain metastases.

Biological aging enhances prognostic stratification beyond chronological age in breast cancer brain metastases.

Journal: Journal of neuro-oncology

Published: January 07, 2026

PIV and PILE scores predict the clinical outcome in patients with metastatic breast cancer treated with CDK4/6 inhibitors.

PIV and PILE scores predict the clinical outcome in patients with metastatic breast cancer treated with CDK4/6 inhibitors.

Journal: International journal of clinical oncology

Published: January 22, 2025

Valuable predictive power of prognostic nutritional index in metastatic breast cancer patients treated with CDK4/6 inhibitors.

Valuable predictive power of prognostic nutritional index in metastatic breast cancer patients treated with CDK4/6 inhibitors.

Journal: Japanese journal of clinical oncology

Published: January 02, 2025

Factors Affecting Survival in Older Patients on Enteral Nutritional Support.

Factors Affecting Survival in Older Patients on Enteral Nutritional Support.

Journal: Journal of evaluation in clinical practice

Published: October 07, 2024

Prognostic value of HER2 2 + expression in patients with TNBC receiving adjuvant capecitabine.

Prognostic value of HER2 2 + expression in patients with TNBC receiving adjuvant capecitabine.

Journal: Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico

Published: October 05, 2024

NELBI score: a new clinical calculator of thirty-day mortality following systemic anticancer therapy in breast cancer patients near the end of life.

NELBI score: a new clinical calculator of thirty-day mortality following systemic anticancer therapy in breast cancer patients near the end of life.

Journal: Breast cancer (Tokyo, Japan)

Published: October 01, 2024

Trastuzumab-induced optic neuritis: "blindness" side effect.

Trastuzumab-induced optic neuritis: "blindness" side effect.

Journal: Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners

Published: August 14, 2024

Showing 1-12 of 16

Last Updated: 09/26/2026